References for this Review were identified through searches of Medline and PubMed for articles from 1966 to February, 2009, by use of the search terms “myasthenia gravis” and “autoimmune myasthenia”. Articles were also identified through searches of the authors' own files. Only papers published in English were reviewed.
ReviewAutoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Introduction
Acquired myasthenia gravis (MG) is a prototypical, antibody-mediated autoimmune disorder of the neuromuscular junction (NMJ).1 In most cases, it is caused by pathogenic autoantibodies directed towards the skeletal muscle acetylcholine receptor (AChR).2 In others, non-AChR components of the postsynaptic muscle endplate, such as the muscle-specific receptor tyrosine kinase (MUSK), might serve as targets for the autoimmune attack.3 The precise origin of the autoimmune response in MG is not known, but abnormalities of the thymus gland (hyperplasia and neoplasia) almost certainly play a part in patients with anti-AChR antibodies,4, 5 and genetic predisposition is also likely to influence which patients develop the disorder.6 Fluctuating muscular weakness that increases with effort is the characteristic manifestation of MG. A wide range of clinical presentations and associated features allow classification of MG into subtypes based on disease distribution (ocular vs generalised), age at onset, thymic abnormalities, and autoantibody profiles. Appropriate recognition of these clinical subtypes helps to determine management strategies and prognosis.
In this Review, we address the latest concepts in the immunopathogenesis of MG relevant to the clinical subtypes, including the role of genetic factors that underlie individual susceptibility to the disease. We discuss the importance of clinical recognition of the various presentations of MG, and the available tests that help to confirm the diagnosis. Finally, we review the evidence that supports the various therapeutic modalities in MG, and develop a current, hierarchical approach to its treatment. Emerging treatment strategies are also delineated, including the prospect of antigen-specific therapy.
Section snippets
Epidemiology
MG is a relatively uncommon disease, although prevalence has increased over time with recent estimates approaching 20 per 100 000 in the US population.7 This increased prevalence is most likely to be due to improved diagnosis and treatment of MG, and an increasing longevity of the population in general. Incidence varies widely from 1·7 to 10·4 per million, depending on the location of study,8 and has been reported to be as high as 21 per million in Barcelona, Spain.9 The occurrence of MG is
Clinical presentation
The clinical hallmark of MG is fatigable weakness, usually involving specific susceptible muscle groups. Patients often note that their weakness fluctuates from day to day or even from hour to hour, worsens with activity, and improves with rest. Patients can have varying degrees of ptosis, diplopia, dysarthria, dysphagia, dyspnea, facial weakness, or fatigable limb or axial weakness (panel 1). Ocular weakness, presenting as fluctuating ptosis and/or diplopia, is the most common initial
MG subtypes
Differences in clinical presentation, age at onset, autoantibody profile, and the presence or absence of thymic pathology allow identification of several MG clinical subtypes (table 1). Patients with generalised MG can be divided into early-onset and late-onset disease, with early-onset MG usually defined as beginning before the age of 40 years.15 These patients are more often female, have anti-AChR antibodies, and enlarged, hyperplastic thymus glands. In addition to anti-AChR antibodies, other
The NMJ in MG
The NMJ has three basic components (figure 1): (1) the presynaptic motor nerve terminal, where acetylcholine is synthesised, stored, and released; (2) the synaptic space; and (3) the postsynaptic muscle membrane, which contains the AChRs and the enzyme acetylcholinesterase. Neuromuscular transmission begins when a nerve action potential enters the nerve terminal and triggers the release of acetylcholine. Exocytosis of synaptic vesicles containing acetylcholine requires calcium, which enters the
Diagnosis
The tests that are available to confirm the clinical diagnosis of MG include bedside tests, such as the edrophonium or ice-pack test, electrophysiological tests, and tests to measure the concentrations of serum autoantibodies (table 2).
Cholinesterase inhibitors
Oral cholinesterase inhibitors increase the amount of acetylcholine available for binding in the NMJ, and are the first-line treatment in patients with MG (table 4).1 Pyridostigmine bromide is the most commonly used cholinesterase inhibitor. The initial oral dose in adults is 15–30 mg every 4–6 h, which is increased and adjusted to maximise benefit and minimise side-effects (diarrhoea, stomach cramps). Pyridostigmine can be given 30–60 mins before meals in patients with bulbar symptoms.
Conclusions and future challenges
There are several emerging therapies for MG, including tacrolimus, rituximab, and antigen-specific apheresis, whereas other treatments await clarification of efficacy and their role in MG (thymectomy, mycophenolate mofetil). In addition, the soluble tumour-necrosis-factor-receptor blocker, etanercept, has been used with some success as a steroid-sparing agent in small numbers of patients with MG, but further study is needed because disease worsening was observed in some patients.159 Preliminary
Search strategy and criteria
References (170)
- et al.
True epithelial hyperplasia in the thymus of early-onset myasthenia gravis: implications for immunopathogenesis
J Neuroimmunol
(2001) - et al.
Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases
Neuromuscul Disord
(2002) - et al.
Prognostic significance of thymomas in patients with myasthenia gravis
Ann Thorac Surg
(2002) - et al.
Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor
Neuromuscul Disord
(2008) - et al.
Novel antibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis
J Neuroimmunol
(2005) - et al.
MuSK-antibody positive myasthenia gravis: questions from the clinic
J Neuroimmunol
(2008) - et al.
How myasthenia gravis alters the safety factor for neuromuscular transmission
J Neuroimmunol
(2008) - et al.
Myasthenia gravis thymus
Am J Pathol
(2007) - et al.
Thymoma
Mayo Clin Proc
(1993) - et al.
Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury
Neuron
(1995)
Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity
Lancet
Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them and correlations with autoantibody status
Am J Pathol
Complement regulators in extraocular muscles and experimental autoimmune myasthenia gravis
Exp Neurol
A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C
Hum Immunol
Concentric needle single fiber electromyography: comparative jitter on voluntary-activated and stimulated extensor digitorum communis
Clin Neurophysiol
Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow
Mayo Clin Proc
Myasthenia gravis
N Engl J Med
Autoimmune response to acetylcholine receptors
Science
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
Nat Med
Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis
Neurology
Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies
Neurology
The epidemiology of myasthenia gravis
Ann N Y Acad Sci
Epidemiologic evidence for a changing natural history of myasthenia gravis
Neurology
Myasthenia gravis. A higher than expected incidence in the elderly
Neurology
Lifetime course of myasthenia gravis
Muscle Nerve
Clinical and serological study of myasthenia gravis in HuBei Province, China
J Neurol Neurosurg Psychiatry
Course and management of myasthenia gravis
JAMA
Distal myasthenia gravis
Neurology
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis
Brain
Associated autoimmune disease in myasthenia gravis. A population-based study
Acta Neurol Scand
Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population based survey in the province of Ferrara, northern Italy
Acta Neurol Scand
The natural course of myasthenia gravis: a long term follow up study
J Neurol Neurosurg Psychiatry
Late onset myasthenia gravis: a changing scene
Arch Neurol
Striational antibodies in myasthenia gravis
Arch Neurol
The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies
Arch Neurol
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features
Eur J Neurol
Paraneoplastic myasthenia gravis: immunological and clinical aspects
Eur J Neurol
Thymoma in patients with MG: characteristics and long-term outcome
Neurology
Disease severity and outcome in thymoma myasthenia: a long-term observational study
Eur J Neurol
The long-term clinical outcome of myasthenia gravis in patients with thymoma
Neurology
Autoantibody profiles and neurological correlations of thymoma
Clin Cancer Res
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis
Ann Neurol
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
Brain
Clinical aspects of MuSK antibody positive seronegative MG
Neurology
Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG
Neurology
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG
Ann Neurol
Seronegative myasthenia gravis
Semin Neurol
Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians
Neurology
Development of generalized disease at 2 years in patients with ocular myasthenia gravis
Arch Neurol
Anti-MuSK antibodies in a case of ocular myasthenia gravis
J Neurol Neurosurg Psychiatry
Cited by (697)
The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis.
2024, Clinical Neurology and NeurosurgeryClinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan
2023, Journal of NeuroimmunologySerum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies
2023, Journal of NeuroimmunologyLong-term efficacy and safety of tacrolimus in young children with myasthenia gravis
2023, Journal of Clinical Neuroscience